Company Profile

JMolner AS is an Estonia-based company primarily engaged in generic drug development for specialty generic pharmaceuticals. The Company also provides analytical chemistry services and cost-saving commercial stability solutions.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	€24.00	-5.51%	2
05/26/05	€25.40	+25.74%	68
02/26/02	€20.20	+3.59%	121
30/26/30	€19.50	-1.52%	55
29/26/29	€19.80	-1.00%	30

Delayed Quote Nasdaq Tallinn

More quotes

Market Closed - Nasdaq Tallinn 08:00:00 06/11/2026 pm IST			5-day change	1st Jan Change
24.00 ^EUR	-5.51%		+23.08%	-14.29%

03/06	J. Molner AS acquired portfolio of US-marketed generic and specialty pharmaceutical products from Nordic Pharma, Inc.	CI
10/24/10	J. Molner AS Strengthens US Market Position with New Product Development Agreement	CI

03/06	J. Molner AS acquired portfolio of US-marketed generic and specialty pharmaceutical products from Nordic Pharma, Inc.	CI
10/24/10	J. Molner AS Strengthens US Market Position with New Product Development Agreement	CI
04/24/04	J. Molner AS Announces Approval and Upcoming Market Launch of Desoximetasone Ointment USP, 0.05%	CI
12/24/12	J. Molner AS Launches Lidocaine HCL Topical Solution USP, 4% in the United States	CI
22/24/22	J. Molner AS Appoints Sten Akel as Chief Financial Officer	CI
02/24/02	The J. Molner Company Appoints Dave Berthold as the New President North America	CI
30/24/30	J. Molner AS Gains US FDA Approval for First Estonian-Developed ANDA - Lidocaine Hydrochloride Topical Solution 4%	CI
04/24/04	J. Molner AS Enters into an Agreement with the US Centers for Medicaid and Medicare Services	CI
07/23/07	Certain Ordinary Shares of J. Molner AS are subject to a Lock-Up Agreement Ending on 7-NOV-2023.	CI
06/23/06	J. Molner AS Signs Licensing Agreement for Five Approved Drugs in the US	CI
07/22/07	J. Molner AS has completed an IPO in the amount of Ã‡1.199998 million.	CI
12/22/12	J. Molner AS has filed an IPO in the amount of Ã‡1.199998 million.	CI

30/09	J Molner : 2026 6 months consolidated unaudited interim report	PU
30/06	J Molner : Decisions of the shareholders - adoption of resolutions of the general meeting without calling a meeting	PU
17/06	J Molner : Chief Financial Officer of J Molner AS resigns	PU
08/06	J Molner : Notice of J. Molner AS Regarding the Adoption of a Shareholders' Resolution Without Convening a General Meeting	PU
08/06	J Molner : Audited Consolidated Annual Report 2025	PU

1 day	-5.51%
1 week	+23.08%
Current month	+23.08%
1 month	+15.38%
3 months	+26.32%
6 months	+0.84%
Current year	-14.29%

J. Molner Share Price

Stocks

MOLNRIPO

EE3100109034

Pharmaceuticals

Chart: J. Molner

Latest news: J. Molner

Press Releases: J. Molner

Quotes and Performance

Price Extremes

Managers and Directors: J. Molner

Generic Pharmaceuticals

Company Profile

Quotes

1 week	19.6	25.4
1 month	19.5	25.4
Current year	10.2	28
1 year	10.2	30.8
3 years	10	32.6
5 years	5	32.6
10 years	5	32.6

Manager	Title	Age	Since
Jason Michael Atticus Grenfell-Gardner PRN	Corporate Officer/Principal	52	01/01/2015
Liina Kervemann DFI	Director of Finance/CFO	-	-
Erik Berlin PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Martin Wilson BRD	Director/Board Member	49	-
Karita Sall BRD	Director/Board Member	52	-
Yoann John Ricau BRD	Director/Board Member	51	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
J. MOLNER	-5.51%	+23.08%	-10.45%	+106.01%	4.81Cr
ELI LILLY AND COMPANY	+0.32%	-3.12%	+46.49%	+130.73%	1,21600Cr
JOHNSON & JOHNSON	+0.82%	+0.37%	+46.65%	+80.75%	66TCr
ABBVIE INC.	+0.95%	-1.28%	+32.91%	+106.18%	51TCr
ROCHE HOLDING AG	-0.36%	-3.25%	+47.17%	+64.58%	38TCr
MERCK & CO., INC.	-0.02%	-1.71%	+71.32%	+40.85%	36TCr
NOVARTIS AG	-0.78%	-0.52%	+30.57%	+57.98%	31TCr
ASTRAZENECA PLC	-0.80%	-0.21%	+8.54%	+35.56%	29TCr
AMGEN INC.	+0.07%	-1.07%	+46.08%	+68.98%	25TCr
GILEAD SCIENCES, INC.	+0.11%	-1.51%	+36.23%	+107.19%	21TCr
Average	-0.61%	+0.01%	+35.55%	+79.88%	41.88TCr
Weighted average by Cap.	+0.12%	+0.03%	+42.70%	+89.18%